Volume 7, Issue 1 (Journal of Clinical and Basic Research (JCBR) 2023)
jcbr 2023, 7(1): 6-8 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Gangavarapu K N, Bora N S, Maddali S, Hasan Q. Frequency of dihydropyrimidine dehydrogenase and UDP-glucuronosyltransferase 1A1 variants in cancer patients requiring chemotherapy: A single-center study in southern India. jcbr 2023; 7 (1) :6-8
URL: http://jcbr.goums.ac.ir/article-1-392-en.html
URL: http://jcbr.goums.ac.ir/article-1-392-en.html
1- Kamineni Academy of Medical Sciences and Research Center, LB Nagar, Hyderabad, Telangana - 500068, India , kvv9007@gmail.com
2- Department of Genetics and Molecular Medicine, Kamineni Hospitals, LB Nagar, Hyderabad, Telangana - 500068, India
3- Department of Oncology, Kamineni Hospitals, LB Nagar, Hyderabad, Telangana - 500068, India
2- Department of Genetics and Molecular Medicine, Kamineni Hospitals, LB Nagar, Hyderabad, Telangana - 500068, India
3- Department of Oncology, Kamineni Hospitals, LB Nagar, Hyderabad, Telangana - 500068, India
Abstract: (880 Views)
Abstract
Background: Cancer treatment using drugs metabolized by the enzymes dihydropyrimidine dehydrogenase (DPYD) and UDP-glucuronosyltransferase 1A1 (UGT1A1) results in adverse effects for some patients. This is frequently reported in cancer patients undergoing therapy with 5-fluorouracil, capecitabine, and irinotecan who have polymorphisms in the genes coding for DPYD and UGT1A1. The present study assessed the DPYD*2A and UGT1A1*28 polymorphisms in cancer patients before starting chemotherapy to identify the individuals at risk of developing an adverse drug reaction.
Methods: Genomic DNA was isolated from patients and subjected to PCR amplification using specific primers to study DPYD*2A and UGT1A1*28 polymorphisms. The PCR products were assessed by Sanger sequencing for establishing the genotype.
Results: Of 75 cancer patients requiring treatment with drugs metabolized by DPYD and UGT1A1, 2 (2.66%) and 12 (29.27%) were likely to have adverse reactions based on DPYD*2A and UGT1A1*28 genotyping, respectively.
Conclusion: Our findings indicate that carrying out genotyping for these two polymorphisms will help a large number of patients requiring treatment with 5-fluorouracil, irinotecan, and capecitabine.
Keywords: Neoplasms, Chemotherapy, Drug therapy, Pharmacogenetics, 5-Fluorouracil, Irinotecan, Enzyme
References
1. Jain AK, Jain S, Rana AC. Metabolic enzyme considerations in cancer therapy. Malays J Med Sci. 2007;14(1):10-7. [View at Publisher] [PMID] [Google Scholar]
2. Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab. 2011;12(5):487-97. [] [DOI] [PMID] [Google Scholar]
3. Del Re M, Di Paolo A, van Schaik RH, Bocci G, Simi P, Falcone A, et al. Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? EPMA Journal. 2010;1(3):495-502. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, et al. Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals. Clin Cancer Res. 2005;11(16):5886-5892. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Matáková T, Halašová E, Škovierová H, Dzian A, Dobrota D, Škereňová M. DPYD genotype and haplotype analysis and colorectal cancer susceptibility in a case-control study from Slovakia. Gen Physiol Biophys. 2017;36(5):557-563. [View at Publisher] [DOI] [PMID] [Google Scholar]
6. Innocenti F, Mills SC, Sanoff H, Ciccolini J, Lenz HJ, Milano G. (2020). All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide. JCO Oncol Pract. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Borràs E, Dotor E, Arcusa A, Gamundi MJ, Hernan I, de Sousa Dias M, et al. High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity. Front Genet. 2013;3:312. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Del Re M, Michelucci A, Di Leo A, Cantore M, Bordonaro R, Simi P, et al. Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. EPMA Journal. 2015;6(1):17. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Dean L. Irinotecan Therapy and UGT1A1 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012. [View at Publisher] [Google scholar]
10. Movva S, Alluri RV, Komandur S, Vattam K, Eppa K, Mukkavali KK, et al. Relationship of angiotensin-converting enzyme gene polymorphism with nephropathy associated with type 2 diabetes mellitus in Asian Indians. Journal of Diabetes and its Complications. 2007;21(4), 237-241. [View at Publisher] [DOI] [PMID] [Google scholar]
11. Poornima S, Subramanyam K, Khan IA, Hasan Q. The insertion and deletion (I28005D) polymorphism of the angiotensin I converting enzyme gene is a risk factor for osteoarthritis in an Asian Indian population. J Renin Angiotensin Aldosterone Syst. 2015;16(4):1281-1287. [View at Publisher] [DOI] [PMID] [Google scholar]
12. Cremolini C, Del Re M, Antoniotti C, Lonardi S, Bergamo F, Loupakis F, et al. DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget. 2017 Dec 21;9(8):7859-7866. [View at Publisher] [DOI] [PMID] [Google scholar]
13. Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA. Pathogenic DPYD Variants and Treatment‐Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta‐Analysis. The Oncologist. 2021;26(12):1008-1016. [View at Publisher] [DOI] [PMID] [Google scholar]
14. Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. 2011;12(9), 1321-1336. [View at Publisher] [DOI] [PMID] [Google scholar]
15. Henricks LM, Lunenburg CA, Meulendijks D, Gelderblom H, Cats A, Swen JJ, et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16(11):1275-1284. [View at Publisher] [DOI] [PMID] [Google scholar]
16. Pavithran K, Ariyannur P, Jayamohanan H, Philip A, Jose WM, Soman S. Dihydropyrimidine dehydrogenase deficiency in patients treated with 5-FU or capecitabine based regimens: A single center experience from South India. Journal of Clinical Oncology. 2021;39(15). [View at Publisher] [DOI] [Google scholar]
17. Saif MW, Mattison L, Carollo T, Ezzeldin H, Diasio RB. Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemother Pharmacol. 2006;58(3):396-401. [View at Publisher] [DOI] [PMID] [Google scholar]
18. Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol. 2016;34(3):227-234. [View at Publisher] [DOI] [PMID] [Google scholar]
19. Jada SR, Lim R, Wong CI, Shu X., Lee SC, Zhou Q, et al. Role of UGT1A1*6,UGT1A1*28andABCG2c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Science. 2007;98(9):1461-1467. [View at Publisher] [DOI] [PMID] [Google scholar]
20. Balram C, Sabapathy K, Fei G, Khoo KS, Lee EJD. Genetic polymorphisms of UDP-glucuronosyltransferase in Asians:UGT1A1* 28 is a common allele in Indians. Pharmacogenetics. 2002;12(1):81-83. [View at Publisher] [DOI] [PMID] [Google scholar]
21. Fujii H, Yamada Y, Watanabe D, Matsuhashi N, Takahashi T, Yoshida K, et al. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. Cancer Chemother Pharmacol. 2019;83(1):123-129. [] [DOI] [PMID] [Google scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).